JP6694269B2 - Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体 - Google Patents

Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体 Download PDF

Info

Publication number
JP6694269B2
JP6694269B2 JP2015540879A JP2015540879A JP6694269B2 JP 6694269 B2 JP6694269 B2 JP 6694269B2 JP 2015540879 A JP2015540879 A JP 2015540879A JP 2015540879 A JP2015540879 A JP 2015540879A JP 6694269 B2 JP6694269 B2 JP 6694269B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
antigen
aureus
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015540879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507470A5 (OSRAM
JP2016507470A (ja
Inventor
セルマン，ブレット
トカチク，クリスティーン
チョードゥリー，パーサ，エス．
ホワ，レイ
パブリク，ピーター
ブォンパーネ，レベッカ
チャン，チュウ−シュン
Original Assignee
メディミューン，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディミューン，エルエルシー filed Critical メディミューン，エルエルシー
Publication of JP2016507470A publication Critical patent/JP2016507470A/ja
Publication of JP2016507470A5 publication Critical patent/JP2016507470A5/ja
Application granted granted Critical
Publication of JP6694269B2 publication Critical patent/JP6694269B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015540879A 2012-11-06 2013-11-06 Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体 Active JP6694269B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261723137P 2012-11-06 2012-11-06
US61/723,137 2012-11-06
US201361782405P 2013-03-14 2013-03-14
US61/782,405 2013-03-14
PCT/US2013/068624 WO2014074540A2 (en) 2012-11-06 2013-11-06 Antibodies to s. aureus surface determinants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019011283A Division JP2019089801A (ja) 2012-11-06 2019-01-25 Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体

Publications (3)

Publication Number Publication Date
JP2016507470A JP2016507470A (ja) 2016-03-10
JP2016507470A5 JP2016507470A5 (OSRAM) 2016-12-22
JP6694269B2 true JP6694269B2 (ja) 2020-05-13

Family

ID=50685304

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015540879A Active JP6694269B2 (ja) 2012-11-06 2013-11-06 Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体
JP2019011283A Withdrawn JP2019089801A (ja) 2012-11-06 2019-01-25 Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019011283A Withdrawn JP2019089801A (ja) 2012-11-06 2019-01-25 Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体

Country Status (16)

Country Link
US (3) US9879070B2 (OSRAM)
EP (2) EP3640338A1 (OSRAM)
JP (2) JP6694269B2 (OSRAM)
KR (1) KR102288394B1 (OSRAM)
CN (2) CN104968797B (OSRAM)
AU (2) AU2013341361A1 (OSRAM)
BR (1) BR112015010125A2 (OSRAM)
CA (1) CA2890427C (OSRAM)
DK (1) DK2917360T3 (OSRAM)
ES (1) ES2776179T3 (OSRAM)
HU (1) HUE049012T2 (OSRAM)
MX (2) MX375324B (OSRAM)
PL (1) PL2917360T3 (OSRAM)
RU (1) RU2698131C2 (OSRAM)
SG (2) SG10201703678TA (OSRAM)
WO (1) WO2014074540A2 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2673373T (pt) 2011-02-08 2018-12-05 Medimmune Llc Anticorpos que ligam especificamente a toxina alfa de staphylococcus aureus e métodos de utilização
KR102111171B1 (ko) 2011-06-10 2020-05-14 메디뮨 엘엘씨 항슈도모나스 ｐｓｌ 결합 분자 및 그의 용도
SMT202000542T1 (it) 2011-11-07 2020-11-10 Medimmune Ltd Terapie di combinazione utilizzando molecole di legame anti-psl e pcrv di pseudomonas
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
EP2793944B1 (en) 2011-12-23 2025-10-08 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
SG10201703677VA (en) 2012-11-06 2017-06-29 Medimmune Llc Methods of treating s. aureus-associated diseases
CA2890427C (en) * 2012-11-06 2022-05-31 Medimmune, Llc Antibodies to s. aureus surface determinants
WO2015187779A1 (en) * 2014-06-03 2015-12-10 Xbiotech, Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
JP2017524943A (ja) * 2014-08-12 2017-08-31 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｓ．アウレウス疾患の予測
WO2016073860A1 (en) * 2014-11-06 2016-05-12 Medimmune, Llc Binding molecules specific for staphylococcus protein a and uses thereof
FR3033333A1 (fr) * 2015-03-06 2016-09-09 Commissariat Energie Atomique Procede et dispositif pour detecter en temps reel un compose secrete et la cible secretrice ainsi que leurs utilisations
CA2978855A1 (en) * 2015-04-17 2016-10-20 Arsanis Biosciences Gmbh Anti-staphylococcus aureus antibody combination preparation
US20190077851A1 (en) * 2015-10-30 2019-03-14 Bruno Francois Methods of using anti-alpha toxin antibody
CN105424930A (zh) * 2015-11-23 2016-03-23 天津科技大学 一种快速检测金黄色葡萄球菌的方法
WO2019067682A1 (en) * 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. BISPECIFIC ANTIGEN-BINDING MOLECULES BINDING TO TARGET STAPHYLOCOCCUS ANTIGEN AND COMPONENT COMPONENT, AND USES THEREOF
CN119176871A (zh) 2018-07-24 2024-12-24 免疫医疗有限责任公司 抗金黄色葡萄球菌凝集因子a(clfa)的抗体
WO2020076789A2 (en) 2018-10-09 2020-04-16 Medimmune, Llc Combinations of anti-staphylococcus aureus antibodies
MX2021004114A (es) 2018-10-09 2021-07-16 Medimmune Llc Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.
CA3127696A1 (en) 2019-02-12 2020-08-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for using bispecific antibodies to bind complement and a target antigen
TW202100549A (zh) 2019-03-13 2021-01-01 美商麥迪紐有限責任公司 降低金黃色葡萄球菌在定殖的患者中之感染
WO2020210650A1 (en) 2019-04-12 2020-10-15 Medimmune, Llc Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用
KR102504175B1 (ko) * 2020-06-17 2023-02-28 (주)옵토레인 항체의 항원 결합 부위에 결합하는 펩타이드, 이를 이용한 약물 복합체, 바이오센서 및 분석 방법
KR102397684B1 (ko) * 2019-12-09 2022-05-13 (주)옵토레인 항체의 항원 결합 부위에 결합하는 펩티드 및 이를 이용한 분석 방법
KR102674109B1 (ko) * 2021-01-14 2024-06-12 (주)옵토레인 스위칭 펩티드, 이를 포함하는 면역분석 장치 및 이를 이용한 면역분석 방법
KR102674098B1 (ko) * 2021-01-14 2024-06-12 (주)옵토레인 스위칭 펩티드 및 이를 이용한 멀티플렉스 면역분석 방법
KR102674120B1 (ko) * 2021-01-18 2024-06-12 (주)옵토레인 스위칭 펩티드 및 이를 이용한 면역분석 방법

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2017198A (en) * 1931-10-17 1935-10-15 Anglada Motor Corp Cuff valve engine
US20030044772A1 (en) * 1997-08-04 2003-03-06 Applied Molecular Evolution [Formerly Ixsys] Methods for identifying ligand specific binding molecules
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
BR0207068A (pt) * 2001-01-26 2004-12-21 Inhibitex Inc Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus
KR20060034231A (ko) 2003-06-06 2006-04-21 메디뮨 인코포레이티드 암의 진단, 치료 및 예방에 있어서의 ｅｐｈａ４ 및ｅｐｈａ４ 조정제의 용도
US7348001B2 (en) * 2003-08-12 2008-03-25 Dyax Corp. Tie1-binding ligands
WO2006017538A2 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US20080050361A1 (en) 2004-10-25 2008-02-28 Heinrichs David E Staphylococcus aureas specific anti-infectives
KR20080113223A (ko) * 2006-03-06 2008-12-29 심포젠 에이/에스 호흡기세포 융합 바이러스 감염 치료용 재조합 폴리클로날 항체
US7910703B2 (en) * 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
AU2007259415B2 (en) 2006-06-12 2013-09-26 Glaxosmithkline Biologicals Sa Use of alpha-toxin for treating and preventing Staphylococcus infections
WO2008152447A2 (en) * 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
US9526774B1 (en) * 2006-11-06 2016-12-27 Microvax, Llc Methods and compositions for suppressing virulence of methicillin resistant Staphylococcus aureus
HUE031614T2 (en) * 2008-01-31 2017-07-28 The Provost Fellows Found Scholars & The Other Members Of Board Of The College Of The Holy & Undiv T Treatment of microbial infections
AU2009246510B2 (en) * 2008-05-12 2014-02-13 Strox Biopharmaceuticals, Llc Staphylococcus aureus-specific antibody preparations
WO2010005513A2 (en) * 2008-06-30 2010-01-14 The Texas A&M University System Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof
WO2010042481A1 (en) * 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
EP2432499A2 (en) * 2009-05-20 2012-03-28 Schering Corporation Modulation of pilr receptors to treat microbial infections
SI2445522T1 (sl) * 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
CA2768204A1 (en) * 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Gram-positive bacteria specific binding compounds
GB0913680D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
WO2011079308A2 (en) * 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
EP2555794A4 (en) * 2010-04-05 2014-01-15 Univ Chicago COMPOSITIONS AND METHODS RELATING TO PROTEIN A (SPA) ANTIBODIES AS IMMUNE REACTION AMPLIFIERS
EP2614074A1 (en) * 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
US20120202047A1 (en) 2011-02-07 2012-08-09 Baker Hughes Incorporated Nano-coatings for articles
PT2673373T (pt) * 2011-02-08 2018-12-05 Medimmune Llc Anticorpos que ligam especificamente a toxina alfa de staphylococcus aureus e métodos de utilização
US9556281B2 (en) * 2011-08-15 2017-01-31 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
PL2794905T3 (pl) * 2011-12-20 2020-11-02 Medimmune, Llc Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych
EP2844275B1 (en) * 2012-04-26 2020-05-13 University of Chicago Staphylococcal coagulase antigens and methods of their use
CA2890427C (en) * 2012-11-06 2022-05-31 Medimmune, Llc Antibodies to s. aureus surface determinants
SG10201703677VA (en) * 2012-11-06 2017-06-29 Medimmune Llc Methods of treating s. aureus-associated diseases
WO2014127200A1 (en) * 2013-02-15 2014-08-21 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
WO2015057893A2 (en) * 2013-10-15 2015-04-23 The Texas A&M University System Compositions and the use of a fibrinogn binding motif presence in efb and coa for vaccine against staphylococcus aureus and drug delivery
US20170023569A1 (en) * 2014-01-10 2017-01-26 University Of Rochester Diagnostic device and method for detection of staphylococcus infection
US9353189B2 (en) * 2014-01-24 2016-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
WO2015187779A1 (en) * 2014-06-03 2015-12-10 Xbiotech, Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2016073860A1 (en) * 2014-11-06 2016-05-12 Medimmune, Llc Binding molecules specific for staphylococcus protein a and uses thereof
CA2978855A1 (en) 2015-04-17 2016-10-20 Arsanis Biosciences Gmbh Anti-staphylococcus aureus antibody combination preparation
US20190077851A1 (en) * 2015-10-30 2019-03-14 Bruno Francois Methods of using anti-alpha toxin antibody
WO2017186928A1 (en) * 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
CA3030154A1 (en) * 2016-07-08 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric dengue/zika viruses live-attenuated zika virus vaccines
CN119176871A (zh) * 2018-07-24 2024-12-24 免疫医疗有限责任公司 抗金黄色葡萄球菌凝集因子a(clfa)的抗体
MX2021004114A (es) * 2018-10-09 2021-07-16 Medimmune Llc Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.
WO2020076789A2 (en) * 2018-10-09 2020-04-16 Medimmune, Llc Combinations of anti-staphylococcus aureus antibodies
TW202100549A (zh) * 2019-03-13 2021-01-01 美商麥迪紐有限責任公司 降低金黃色葡萄球菌在定殖的患者中之感染

Also Published As

Publication number Publication date
ES2776179T3 (es) 2020-07-29
US11447543B2 (en) 2022-09-20
MX2015005477A (es) 2015-11-30
US20200407429A1 (en) 2020-12-31
US20150291685A1 (en) 2015-10-15
WO2014074540A2 (en) 2014-05-15
AU2018241107B2 (en) 2020-09-17
US10730934B2 (en) 2020-08-04
CN104968797A (zh) 2015-10-07
RU2015121624A (ru) 2016-12-27
JP2019089801A (ja) 2019-06-13
CN104968797B (zh) 2018-11-30
KR102288394B1 (ko) 2021-08-09
AU2018241107A1 (en) 2018-10-25
DK2917360T3 (da) 2020-03-30
MX2022008079A (es) 2022-07-11
PL2917360T3 (pl) 2020-06-29
US9879070B2 (en) 2018-01-30
BR112015010125A2 (pt) 2017-08-22
EP2917360A2 (en) 2015-09-16
US20190016787A1 (en) 2019-01-17
SG11201503232TA (en) 2015-05-28
HK1215452A1 (zh) 2016-08-26
CN109553681A (zh) 2019-04-02
RU2019122610A (ru) 2020-02-18
HUE049012T2 (hu) 2020-09-28
EP3640338A1 (en) 2020-04-22
CA2890427A1 (en) 2014-05-15
CA2890427C (en) 2022-05-31
SG10201703678TA (en) 2017-06-29
AU2013341361A1 (en) 2015-06-04
HK1215054A1 (en) 2016-08-12
MX375324B (es) 2025-03-06
EP2917360A4 (en) 2017-01-25
WO2014074540A3 (en) 2014-07-10
KR20150094621A (ko) 2015-08-19
EP2917360B1 (en) 2020-01-08
JP2016507470A (ja) 2016-03-10
RU2698131C2 (ru) 2019-08-22

Similar Documents

Publication Publication Date Title
JP6694269B2 (ja) Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体
TWI719938B (zh) 多重細菌感染之治療
EP2464665B1 (en) Human monoclonal antibody against s. aureus derived alpha-toxin and its use in treating or preventing abscess formation
TW202126684A (zh) 抗α-溶血素的抗體及其應用
JP2022512647A (ja) 抗黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）抗体の組み合わせ
JP2018513168A (ja) 抗スタフィロコッカス・アウレウス抗体組み合わせ製剤
JP2017505758A (ja) 黄色ブドウ球菌のｌｕｋｇｈ（ｌｕｋａｂ）毒素に対する抗体及び抗体配列
JP2022512904A (ja) 抗Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ抗体およびその使用
EP3441474B1 (en) Pharmaceutical compositions containing a mutated leukocidin e
HK40025295A (en) Antibodies to s. aureus surface determinants
RU2808018C2 (ru) Антитела к поверхностным детерминантам s. aureus
HK1215452B (zh) 金黃色葡萄球菌表面決定簇的抗體
HK1215054B (en) Antibodies to s. aureus surface determinants
HK40004629B (en) Pharmaceutical compositions containing a mutated leukocidin e
HK40004629A (en) Pharmaceutical compositions containing a mutated leukocidin e
BR112012002892A2 (pt) anticorpo monoclonal específico para a alfa-toxina de s. aureus, hibridoma, ácido nucleico, vetor, célula hospedeira, método para produzir o anticorpo monoclonal, composição farmacêutica, uso de um anticorpo monoclonal e kit de teste para o diagnóstico de uma infecção de s. aureus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200417

R150 Certificate of patent or registration of utility model

Ref document number: 6694269

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250